Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation

Journal of Heart and Lung Transplantation

Volumn 36, Issue 5, 2017, Pages 540-545

  Clerkin, Kevin J ^a   Farr, Maryjane A ^a   Restaino, Susan W ^a   Zorn, Emmanuel ^a   Latif, Farhana ^a   Vasilescu, Elena R ^a   Marboe, Charles C ^a   Colombo, Paolo C ^a   Mancini, Donna M ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

antibody mediated rejection; cardiac allograft vasculopathy; donor specific antibodies; heart transplant; mortality

Indexed keywords

DONOR SPECIFIC HLA ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ALLOGRAFT; ANTIBODY SPECIFICITY; COHORT ANALYSIS; DONOR; FOLLOW UP; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

ADULT; ALLOGRAFTS; ANTIBODY SPECIFICITY; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REOPERATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; UNITED STATES;

EID: 85007439898     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.10.016     Document Type: Article

References (23)

1. 1 Valenzuela, N.M., Reed, E.F., Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol 1034 (2013), 41–70.
2. 2 George, J.F., Kirklin, J.K., Shroyer, T.W., et al. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. J Heart Lung Transplant 14 (1995), 856–864.
3. 3 Kaczmarek, I., Deutsch, M.A., Kauke, T., et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 6 (2008), 229–235.
4. 4 Taylor, D.O., Yowell, R.L., Kfoury, A.G., Hammond, E.H., Renlund, D.G., Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 19 (2000), 518–521.
5. 5 Topilsky, Y., Gandhi, M.J., Hasin, T., et al. Donor specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy—a 3-D volumetric IVUS study. Transplantation 95 (2013), 389–396.
6. 6 Smith, J.D., Banner, N.R., Hamour, I.M., et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 11 (2011), 312–319.
7. 7 Tambur, A.R., Pamboukian, S.V., Costanzo, M.R., et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 80 (2005), 1019–1025.
8. 8 Ho, E.K., Vlad, G., Vasilescu, E.R., et al. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol 72 (2011), 5–10.
9. 9 Stewart, S., Winters, G.L., Fishbein, M.C., et al. Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. J Heart Lung Transplant 24 (2005), 1710–1720.
10. 10 Kobashigawa, J., Crespo-Leiro, M.G., Ensminger, S.M., et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30 (2011), 252–269.
11. 11 Ware, A.L., Malmberg, E., Delgado, J.C., et al. The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children. J Heart Lung Transplant 35 (2016), 179–185.
12. 12 Berry, G.J., Burke, M.M., Andersen, C., et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 32 (2013), 1147–1162.
13. 13 Mehra, M.R., Crespo-Leiro, M.G., Dipchand, A., et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 29 (2010), 717–727.
14. 14 Clerkin, K.J., Restaino, S.W., Zorn, E., Vasilescu, E.R., Marboe, C.C., Mancini, D.M., The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection. J Heart Lung Transplant 35 (2016), 1059–1066.
15. 15 Coutance, G., Ouldamar, S., Rouvier, P., et al. Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy. J Heart Lung Transplant 34 (2015), 1050–1057.
16. 16 Coutance, G., Ouldamar, S., Rouvier, P., et al. Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy. The J Heart Lung Transplant 34 (2015), 1050–1057.
17. 17 Hodges, A.M., Lyster, H., McDermott, A., et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 93 (2012), 650–656.
18. 18 Loupy, A., Toquet, C., Rouvier, P., et al. Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection. Am J Transplant 16 (2016), 111–120.
19. 19 Adatya, S., Delijkich, E., Hiller, D., Sayer, G., Yee, J., Uriel, N., Utility of gene expression (Allomap Score) in antibody mediated rejection detection. J Heart Lung Transplant 35 (2016), S33–S34.
20. 20 Colvin, M.M., Cook, J.L., Chang, P., et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation 131 (2015), 1608–1639.
21. 21 Murata, K., Baldwin, W.M., Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody mediated rejection. Transplant Rev (Orlando) 23 (2009), 139–150.
22. 22 Murata, K., Fox-Talbot, K., Qian, Z., et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant 7 (2007), 2605–2614.
23. 23 Reed, E.F., Rao, P., Zhang, Z., et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 13 (2013), 1859–1870.